Treasurer of the State of North Carolina Cuts Position in Teleflex Incorporated (NYSE:TFX)

Treasurer of the State of North Carolina decreased its holdings in Teleflex Incorporated (NYSE:TFX) by 13.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 19,252 shares of the medical technology company’s stock after selling 3,116 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Teleflex were worth $6,375,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TFX. BlackRock Inc. raised its holdings in Teleflex by 6.9% in the second quarter. BlackRock Inc. now owns 4,044,235 shares of the medical technology company’s stock valued at $1,339,247,000 after buying an additional 259,880 shares during the period. Invesco Ltd. raised its holdings in Teleflex by 29.3% in the second quarter. Invesco Ltd. now owns 870,117 shares of the medical technology company’s stock valued at $288,139,000 after buying an additional 197,426 shares during the period. Marshall Wace LLP raised its holdings in Teleflex by 26.7% in the second quarter. Marshall Wace LLP now owns 756,383 shares of the medical technology company’s stock valued at $250,476,000 after buying an additional 159,606 shares during the period. Point72 Asset Management L.P. raised its holdings in Teleflex by 162.8% in the second quarter. Point72 Asset Management L.P. now owns 233,638 shares of the medical technology company’s stock valued at $77,369,000 after buying an additional 144,730 shares during the period. Finally, First Trust Advisors LP raised its holdings in Teleflex by 247.5% in the first quarter. First Trust Advisors LP now owns 181,850 shares of the medical technology company’s stock valued at $54,948,000 after buying an additional 129,524 shares during the period. Hedge funds and other institutional investors own 90.40% of the company’s stock.

In other news, Director Benson Smith sold 8,500 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $332.65, for a total transaction of $2,827,525.00. Following the completion of the sale, the director now owns 85,300 shares of the company’s stock, valued at $28,375,045. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas E. Powell sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $355.52, for a total transaction of $2,666,400.00. Following the sale, the chief financial officer now directly owns 18,197 shares of the company’s stock, valued at approximately $6,469,397.44. The disclosure for this sale can be found here. Insiders have sold 42,104 shares of company stock valued at $14,357,448 in the last three months. Corporate insiders own 2.36% of the company’s stock.

Shares of NYSE:TFX opened at $330.08 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.52 and a debt-to-equity ratio of 0.82. Teleflex Incorporated has a 52-week low of $226.02 and a 52-week high of $373.90. The company has a 50 day moving average of $350.02 and a two-hundred day moving average of $323.77. The company has a market capitalization of $15.33 billion, a price-to-earnings ratio of 33.34, a price-to-earnings-growth ratio of 2.15 and a beta of 0.98.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 1st. The medical technology company reported $2.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.59 by $0.07. Teleflex had a net margin of 10.78% and a return on equity of 18.57%. The company had revenue of $652.50 million during the quarter, compared to the consensus estimate of $637.06 million. During the same quarter last year, the company earned $2.47 earnings per share. Teleflex’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities analysts anticipate that Teleflex Incorporated will post 11.03 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend was Wednesday, August 14th. Teleflex’s payout ratio is currently 13.74%.

Several research firms recently commented on TFX. Morgan Stanley raised their price target on shares of Teleflex from $345.00 to $392.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. JMP Securities increased their price objective on shares of Teleflex from $325.00 to $395.00 and gave the company a “market outperform” rating in a research report on Monday, August 5th. ValuEngine downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Raymond James increased their price objective on shares of Teleflex from $350.00 to $420.00 and gave the company a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Barclays increased their price objective on shares of Teleflex from $309.00 to $356.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $374.45.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Story: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.